chevron_leftBack
As of 13 June 2026, Biofrontera Inc. has a market cap of $12.81M USD, ranking #39925 globally and #5223 in the United States.
It ranks #3559 in the Healthcare sector, and #1163 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$12.81MUSD
Enterprise Value
$12.63MUSD
Revenue (TTM)
$41.71MUSD
EBITDA (TTM)
-$11.21MUSD
Net Income (TTM)
-$10.54MUSD
EBITDA Margin
-27%
Profit Margin
-25%
PS Ratio
0.3
PB Ratio
1.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Hermann Luebbert
open_in_new
Employees
94
Founded
1997
IPO
29 Oct 2021
Website
biofrontera-us.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.8% | 1.8% | 36% | 13% | 4.7% | 32% |
News
Loading...
BFRI Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BFRI
Biofrontera Inc
ISIN: US09077D2099
Shares Out.:
Shares Outstanding:
12.803M1
Shares Float:
10.888M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.10 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
6M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
4M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
3M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
2M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
1M%
|
19.5
|
|
NYSE: BMY
|
$117.58B
918K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
3M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
2M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
2M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
1M%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
859K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
846K%
80.96B GBP
|
14.6
|
chevron_leftBack